Fate Therapeutics (FATE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FATE Fate Therapeutics

Watchlist

1.830
-0.095-4.94%

Close Dec 13 16:00 ET

1.860
+0.030+1.62%

Post 16:28 ET

208.43MMarket Cap-1.12P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsDec 11 04:31 ET · Ratings
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3
Moomoo NewsDec 10 05:33 ET · Ratings
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
TipRanksDec 10 04:45 ET · Ratings
Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits
MT NewswiresDec 9 17:41 ET
Express News | Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus
ReutersDec 9 16:01 ET
TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating
Moomoo NewsDec 6 07:33 ET · Ratings

Comments

105095009

Dec 10 08:40

$Fate Therapeutics (FATE.US)$ lets go

Jaguar8

Dec 9 21:04

🟡Watchlist TUESDAY December 10. NFA.

NOTE: There are a lot on my watchlist today which did not yet run. Please do include them in your watchlist up to next week because there are delayed market reactions to news overshadowed by runners.
$Chimerix (CMRX.US)$ PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...

Jaguar8

Dec 9 15:05

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Fate Therapeutics (NASDAQ: FATE)presented new Phase 1 clinical data for FT819, its off-the-shelf CAR T-cell therapy for systemic lupus erythematosus (SLE). Three patients with active lupus nephritis received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells.
The treatment showed promising ...

Comment allez vous

Nov 26 08:11

Roche 😙

$Fate Therapeutics (FATE.US)$ Roche buying Fate too?

liang wang199

Nov 18 11:21

There will be a big rise soon.

Heat List

Overall

No Data